At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 105 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Daratumumab for Advanced Cancer. Completed, enrolled 105 participants across 20 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesAustralia, Canada, France, Germany, Italy, Puerto Rico, Spain, Switzerland, United States
CollaboratorsJanssen Biotech, Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartJun 2017
Primary CompletionJul 2020
TodayJul 2026
First PostedMar 31, 2017
Enrollment StartJun 15, 2017
Primary CompletionJul 6, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.3 years ago
Interventions
Nivolumabbiological
Specified dose on specified days
Daratumumabbiological
Specified dose on specified days